Fatigue in multiple sclerosis;Zespół zmeczenia w stwardnieniu rozsianym

Neurologia i Neurochirurgia Polska

Volumn 43, Issue 1, 2009, Pages 71-76

  Dworzońska, Ewa ^a   Mitosek Szewczyk, Krystyna ^a   Stelmasiak, Zbigniew ^a  

^a Uniwersytet Medyczny   (Poland)

Author keywords

Fatigue; Fatigue syndrome; Multiple sclerosis

Indexed keywords

AMANTADINE; INTERLEUKIN 1BETA; INTERLEUKIN 6; MODAFINIL; PEMOLINE; TUMOR NECROSIS FACTOR ALPHA;

APATHY; CHRONIC FATIGUE SYNDROME; CYTOKINE PRODUCTION; DISEASE SEVERITY; DOSE RESPONSE; EXHAUSTION; FATIGUE; FATIGUE IMPACT SCALE; FATIGUE SEVERITY SCALE; HUMAN; MULTIPLE SCLEROSIS; PATHOPHYSIOLOGY; QUALITY OF LIFE; RATING SCALE; REVIEW;

FATIGUE; FATIGUE SYNDROME, CHRONIC; HUMANS; MULTIPLE SCLEROSIS; SEVERITY OF ILLNESS INDEX;

EID: 65949109699     PISSN: 00283843     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (49)

1. Hadjimichael O., Vollmer T., Oleen-Burkey M.; North American Research Committee on Multiple Sclerosis. Fatique characteristics in multiple sclerosis: the North American Research Committee on Multiple Sclerosis (NARCOMS) survey. Health Qual Life Outcomes 2008; 6: 100.
2. Burnett R. Fatigue. Lancet 2005; 366: 21.
3. Giovanni G. Multiple sclerosis related fatigue. J Neurol Neurosurg Psychiatry 2006; 77: 2-3.
4. Hämäläinen P. Understanding cognitive changes. MS in Focus 2004; 4: 13-15.
5. Losy J. Zmeczenie w stwardnieniu rozsianym. Farmakoter Psychiatr Neurolog 2005; 3: 279-282.
6. Brola W., Ziomek M., Czernicki J. Zespół zmeczenia w przewlekłych chorobach neurologicznych. Neurol Neurochirur Pol 2007; 41: 340-349.
7. Schapiro R.T. Managing symptoms of multiple sclerosis. Neurol Clin 2005; 23: 177-187.
8. Krupp L.B., Alvarez L.A., LaRocca N.G. i wsp. Clinical characteristics of fatigue in multiple sclerosis. Arch Neurol 1988; 45: 435-437.
9. Ford H., Trigwell P., Johnson M. The nature of fatigue in multiple sclerosis. J Psychosom Res 1998; 45: 33-38.
10. Djaldetti R., Ziv I., Achiron A. i wsp. Fatigue in multiple sclerosis compared with chronic fatigue syndrome: a quantitative assessment. Neurology 1996; 46: 632-635.
11. Trojan D., Arnold D., Collet J.P. i wsp. Fatigue in multiple sclerosis: association with disease-related, behavioural and psychosocial factors. Mult Scler 2007; 13: 985-995.
12. Multiple Sclerosis Council for Clinical Practice Guidelines. Fatigue and multiple sclerosis: evidence based strategies for fatigue in multiple sclerosis. Paralyzed Veterans of America, Washington 1998.
13. Roecke U., Kappos L., Lechner-Scott J. i wsp. Reduced glucose metabolism in the frontal cortex and basal ganglia of multiple sclerosis patients with fatigue. Neurology 1977; 48: 1566-1571.
14. Scott L.V., Dinan T.G. The neuroendocrinology of chronic fatigue syndrome: focus on the hypothalamic-pituitary-adrenal axis. Funct Neurol 1999; 14: 3-11.
15. Tellez N., Comabella M., Julia E. i wsp. Fatigue in progressive multiple sclerosis is associated with low lewels of dehydroepiandrosterone. Mult Scler 2006; 12: 487-494.
16. Kelley K.W., Bluthe R.M., Dantzer R. i wsp. Cytokine-induced sickness behavior. Brain Behav Immun 2003; 17 (Suppl 1): S112-S118.
17. Heesen C., Nawrath L., Reich C. i wsp. Fatigue in multiple sclerosis: an example of cytokine mediated sickness behaviour? J Neurol Neurosurg Psychiatry 2006; 77: 34-39.
18. Rönnbäck L., Hansson E. On the potential role of glutamate transport in mental fatigue. J Neuroinflammation 2004; 1: 22.
19. Bertolene K., Coyle P.K., Krupp L.B. Cytokine correlates of fatigue in MS. Neurology 1993; 43: 356.
20. Koch M., Uyttenboogaart M., van Harten A. i wsp. Fatigue, depression and progression in multiple sclerosis. Mult Scler 2008; 14: 815-822.
21. Chaudhuri A., Behan P.O. Fatigue and basal ganglia. J Neurol Sci 2000; 179: 34-42.
22. Krupp L.B., Pollina D.A. Mechanisms and management of fatigue in progressive neurological disorders. Curr Opin Neurol 1996; 9: 456-460.
23. Chaudhuri A., Behan W.M., Behan P.O. Chronic fatigue syndrome. Proc R Coll Physicians Edinb 1998; 28: 150-163.
24. Chaudhuri A., Behan P. O. Neurological dysfunction in chronic fatigue syndrome. J Chronic Fatigue Syndr 2000; 6: 51-68.
25. Latash M., Kalugina E., Nicholas J. i wsp. Myogenic and central neurogenic factors in fatigue in MS. Mult Scler 1996; 1: 236-241.
26. Filippi M., Rocca M.A., Colombo B. i wsp. Functional magnetic resonance imaging correlates of fatigue in multiple sclerosis. Neuroimage 2002; 15: 559-567.
27. Comi G., Leocani L., Rossi P. i wsp. Physiopathology and treatment of fatigue in multiple sclerosis. J Neurol 2001; 248: 174-179.
28. Kos D., Nagels G., D'Hooghe M.B. i wsp. A rapid screening tool for fatigue impact in multiple sclerosis. BMC Neurol 2006; 6: 27.
29. Tellez N., Rio J., Tintore M. i wsp. Does the Modified Fatigue Impact scale offer a more comrehensive assessment of fatigue in MS? Mult Scler 2005; 11: 198-202.
30. Zifko U.A. Management of fatigue in patients with: multiple sclerosis. Drugs 2004; 64: 1295-1304.
31. Dittner A.J., Wessely S.C., Brown R.G. The assessment of fatigue: a practical guide for clinicians and researchers. J Psychosom Res 2004; 56: 157-170.
32. Schwartz J., Jandorf L., Krupp L.B. The measurement of fatigue: a new scale. J Psychosom Res 1993; 37: 753-762.
33. Stanton B.R., Barnes F., Silber E. Sleep and fatigue in multiple sclerosis. Mult Scler 2006; 12: 481-486.
34. Krupp L.B., LaRocca N.G., Muir-Nash J. i wsp. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 1989; 46: 1121-1123.
35. Bergamaschi R., Romani A., Versino M. Clinical aspects of fatigue in multiple sclerosis. Funct Neurol 1997; 12: 247-251.
36. Krupp L.B. Fatigue in multiple sclerosis. CNS Drugs 2003; 17: 225-234.
37. Chaudhuri A., Behan P.O. Fatigue and basal ganglia. J Neurol Sci 2000; 179: 34-42.
38. Krupp L.B., Pollina D.A. Mechanisms and management of fatigue in progressive neurological disorders. Curr Opin Neurol 1996; 9: 456-460.
39. Heesen C. Exercise and MS fatigue. Mult Scler 2007; 13: S7-S273.
40. Astrand P.O. Exercise physiology and it is role in disease prevention and in rehabilitation. Arch Phys Med Rehabil 1987; 68: 305-309.
41. Petajan J.H., Gappmaier E., White A.T. i wsp. Impact of aerobic training on fitness and quality of life in multiple sclerosis. Ann Neurol 1996; 39: 432-441.
42. Bartosik-Psujek H., Stelmasiak Z. Stwardnienie rozsiane - trudne odpowiedzi na proste pytania. Neurol Neurochir Pol 2006; 40: 441-445.
43. Rossini P.M., Pasqualetti P., Pozzilli C. i wsp. Fatigue in progressive multiple sclerosis: results of a randomized double-blind, placebo-controlled, crossover trial of oral 4- aminopirydine. Mult Scler 2001; 7: 354-358.
44. Mostert S., Kesselring J. Effects of a short-term exercise training program on aerobic fitness, fatigue, health perception and activity level of subjects with multiple sclerosis. Mult Scler 2002; 8: 161-168.
45. Wingerchuk D.M., Benarroch E.E., O'Brien P.C. i wsp. A randomized controlled placebo crossover trial of aspirin for fatigue in multiple sclerosis. Neurology 2005; 64: 1267-1269.
46. Branas P., Jordan R., Fry-Smith A. i wsp. Treatments for fatigue in multiple sclerosis: a rapid and systematic review. Health Technol Assess 2000; 4: 1-61.
47. Lee D., Newell R., Ziegler L. i wsp. Treatment of fatigue in multiple sclerosis: a systematic review of the literature. Int J Nurs Pract 2008; 14: 81-93.
48. Neilley L.K, Goodin D.S, Goodkin D.E. i wsp. Side effect profile of interferon beta-1b in MS: Results of an open label trial. Neurology 1996; 46: 552-554.
49. Zinvandov R., Zorzon M., Tommasi M. A. i wsp. A longitudinal study of quality of life and side effects in patients with multiple sclerosis treated with interferon beta-1a. J Neurol Sci 2003; 216: 113-118.